Assignee
VION PHARMACEUTICALS INC
US·16 granted patents·5 pending applications·680 citations·filing 1996–2008
Top patents by PatentIndex Score
21 records- 0198US7514089B2Genetically modified tumor-targeted bacteria with reduced virulenceVION PHARMACEUTICALS INC·Filed 2005·Granted Apr 7, 2009·52 cites·12 claims
- 0298US7354592B2Genetically modified tumor-targeted bacteria with reduced virulenceVION PHARMACEUTICALS INC·Filed 2005·Granted Apr 8, 2008·63 cites·13 claims
- 0396US6863894B2Genetically modified tumor-targeted bacteria with reduced virulenceVION PHARMACEUTICALS INC·Filed 2002·Granted Mar 8, 2005·66 cites·25 claims
- 0495US6080849AGenetically modified tumor-targeted bacteria with reduced virulenceVION PHARMACEUTICALS INC·Filed 1997·Granted Jun 27, 2000·116 cites·13 claims
- 0594US7452531B2Compositions and methods for tumor-targeted delivery of effector moleculesVION PHARMACEUTICALS INC·Filed 2005·Granted Nov 18, 2008·51 cites·24 claims
- 0694US6447784B1Genetically modified tumor-targeted bacteria with reduced virulenceVION PHARMACEUTICALS INC·Filed 1998·Granted Sep 10, 2002·107 cites·22 claims
- 0793US6962696B1Compositions and methods for tumor-targeted delivery of effector moleculesVION PHARMACEUTICALS INC·Filed 2000·Granted Nov 8, 2005·77 cites·9 claims
- 0887US6475482B1Genetically modified tumor-targeted bacteria with reduce virulenceVION PHARMACEUTICALS INC·Filed 1999·Granted Nov 5, 2002·57 cites·14 claims
- 0985US6855695B2Water-soluble SHPs as novel alkylating agentsVION PHARMACEUTICALS INC·Filed 2003·Granted Feb 15, 2005·26 cites·73 claims
- 1078US7405317B2Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agentsVION PHARMACEUTICALS INC·Filed 2005·Granted Jul 29, 2008·3 cites·11 claims
- 1174US5767134AProdrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMPVION PHARMACEUTICALS INC·Filed 1997·Granted Jun 16, 1998·37 cites·21 claims
- 1272US6458816B1Modified prodrug forms of AP/AMPVION PHARMACEUTICALS INC·Filed 2001·Granted Oct 1, 2002·6 cites·59 claims
- 1365US5869676AProcess for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMPVION PHARMACEUTICALS INC·Filed 1997·Granted Feb 9, 1999·13 cites·12 claims
- 1462US2004229338A1Compositions and methods for tumor-targeted delivery of effector moleculesVION PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 1559US7273714B2Alkylguanyltransferase assaysVION PHARMACEUTICALS INC·Filed 2006·Granted Sep 25, 2007·0 cites·17 claims
- 1654US2009075945A1Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agentsVION PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1752US2003113293A1Compositions and methods for delivery of an agent using attenuated Salmonella containing phageVION PHARMACEUTICALS INC·Filed 2002·Application pending·0 cites
- 1851US2008299556A2Alkylguanyltransferase AssaysVION PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1951US2005043244A1Water-soluble SHPs as novel alkylating agentsVION PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 2048US6005097AProcesses for high-yield diastereoselective synthesis of dideoxynucleosidesVION PHARMACEUTICALS INC·Filed 1996·Granted Dec 21, 1999·6 cites·19 claims
- 2145US7605137B2Combination therapy comprising cloretazineVION PHARMACEUTICALS INC·Filed 2005·Granted Oct 20, 2009·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when VION PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →